Triglycerides: A case for treatment?

Current Opinion in Cardiology

Volumn 27, Issue 4, 2012, Pages 398-404

  Wierzbicki, Anthony S ^a   Clarke, Rosemary E ^a   Viljoen, Adie ^b   Mikhailidis, Dimitri P ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cardiovascular disease; fibrate; insulin resistance; lipid lowering drug; metabolic syndrome; niacin; omega 3 fatty acid; statin; triglyceride

Indexed keywords

ACETYLSALICYLIC ACID; BEZAFIBRATE; BILE ACID SEQUESTRANT; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; ROSIGLITAZONE; STATIN; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; HUMAN; INSULIN RESISTANCE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MONOTHERAPY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW;

EID: 85027956505     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328353adc1     Document Type: Review

References (81)

1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
2. Viljoen A, Wierzbicki AS. Investigating mixed hyperlipidaemia. BMJ 2011; 343:d5146.
3. Bruckert E, Baccara-Dinet M, McCoy F, et al. High prevalence of low HDLcholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005; 21:1927-1934.
4. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet 2010; 375:1634-1639.
5. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Avidence and guidance for management. Eur Heart J 2011; 32:1345-1361.
6. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007; 115:450-458.
7. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361:777-780.
8. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. Lancet 2008; 372:224-233.
9. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992; 70:3H-9H.
10. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-Analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-219.
11. Assmann G, Schulte H. The importance of triglycerides: Results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992; 8 (Suppl 1):99-103.
12. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-Aged men. Am J Cardiol 1996; 77:1179-1184.
13. Hopkins PN, Wu LL, Hunt SC, et al. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005; 45:1003-1012.
14. Gaudet D, De Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010; 11:55-60.
15. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: A critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002; 48:236-254.
16. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102:1K-34K.
17. Mikhailidis DP, Elisaf M, Rizzo M, et al. 'European panel on low density lipoprotein (LDL) subclasses': A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: Axecutive summary. Curr Vasc Pharmacol 2011; 9:531-532.
18. Mikhailidis DP, Elisaf M, Rizzo M, et al. 'European panel on low density lipoprotein (LDL) subclasses': A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9:533-571.
19. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010; 375:181-183.
20. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419.
21. Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011; 9:292-301.
22. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of nonfasting and postprandial triglycerides: An expert panel statement. Curr Vasc Pharmacol 2011; 9:258-270.
23. Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: A meta-Analysis. Curr Vasc Pharmacol 2011; 9:271-280.
24. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: A meta-Analysis. Am J Clin Nutr 1992; 56:320-328.
25. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356:2119-2125.
26. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155-161.
27. Niswender K. Diabetes and obesity: Therapeutic targeting and risk reduction: A complex interplay. Diabetes Obes Metab 2010; 12:267-287.
28. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
29. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477-484.
30. The Scandinavian Simvastatin Survival Study (4S) investigators. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345:1274-1275.
31. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
32. May P, Woldt E, Matz RL, et al. The LDL receptor-related protein (LRP) family: An old family of proteins with new physiological functions. Ann Med 2007; 39:219-228.
33. Bilheimer DW. The lipoprotein receptor concept. Drugs 1988; 36 (Suppl 3):55-62.
34. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81:66B-69B.
35. Wierzbicki AS, Lumb PJ, Chik G, et al. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol 2000; 86:547-549; A9.
36. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128-133.
37. Sniderman AJ. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: Implications for clinical practice. J Clin Lipidol 2008; 2:36-42.
38. Wierzbicki AS, Morrell J, Hemsley D, et al. The effect of fibrate-statin combination therapy on cardiovascular events: A retrospective cohort analysis. Curr Med Res Opin 2010; 26:2141-2146.
39. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: Position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21:959-969.
40. Manghat P, Wierzbicki AS. Colesevelam: A specifically engineered Bile Acid Sequestrant. Future Lipidol 2008; 3:237-255.
41. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009; 15:490-516.
42. Wierzbicki AS. Niacin: The only vitamin that reduces cardiovascular events. Int J Clin Pract 2011; 65:379-385.
43. Wierzbicki AS. FIELDS of dreams, fields of tears: A perspective on the fibrate trials. Int J Clin Pract 2006; 60:442-449.
44. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 2009; 24:372-379.
45. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
46. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-Aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
47. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006; 97:477-479.
48. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Lancet 1984; 2:600-604.
49. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
50. Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21-27.
51. Rubins HB. Triglycerides and coronary heart disease: Implications of recent clinical trials. J Cardiovasc Risk 2000; 7:339-345.
52. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT - A randomized controlled trial. JAMA 2001; 285:1585-1591.
53. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366:1849-1861.
54. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease: A pooled meta-Analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154:943-953.
55. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-Analysis. Lancet 2010; 375:1875-1884.
56. Wierzbicki AS. Fibrates: No ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol 2010; 21:352-358.
57. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A metaanalysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-197.
58. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
59. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
60. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
61. AIM-HIGH investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011; 161:538-543.
62. AIM-HIGH investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011; 161:471-477.
63. HPS2-THRIVE investigators. A Randomized Trial of the Long-Term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant. Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). ClinicalTrials.gov NCT00461630. http://clinicaltrials.gov/ ct2/show/NCT00461630. [Accessed 10 January 2012]
64. Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: A prospective, randomized crossover study. Diabetes Metab Res Rev 2007; 23:392-399.
65. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009; 373:2125-2135.
66. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366:1279-1289.
67. Denke MA. Dietary fats, fatty acids, and their effects on lipoproteins. Curr Atheroscler Rep 2006; 8:466-471.
68. Feldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 2007; 32:46-60.
69. Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 2008; 197:12-24.
70. Wierzbicki AS. A fishy business: Omega-3 fatty acids and cardiovascular disease. Int J Clin Pract 2008; 62:1142-1146.
71. Konig A, Bouzan C, Cohen JT, et al. A quantitative analysis of fish consumption and coronary heart disease mortality. Am J Prev Med 2005; 29:335-346.
72. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682-690.
73. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447-455.
74. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090-1098.
75. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223-1230.
76. Investigators Gissi-HF, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, doubleblind, placebo-controlled trial. Lancet 2008; 372:1231-1239.
77. Athyros VG, Kakafika AI, Wierzbicki AS, et al. Targeting triglycerides in secondary prevention: Should we bother? Int J Clin Pract 2009; 63:15-18.
78. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs 2001; 1:327-336.
79. Cubbon RM, Wheatcroft SB, Grant PJ, et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: A comparison of over 3000 patients between 1995 and 2003. Eur Heart J 2007; 28:540-545.
80. Vamos EP, Millett C, Parsons C, et al. Nationwide Study on Trends in Hospital Admissions for Major Cardiovascular Events and Procedures Among People With and Without Diabetes in England, 2004-2009. Diabetes Care 2012; 35:265-272.
81. HeartWire. FDA issues 'safety communication' on fenofibrate. TheHEART. org. 2011. http://www.theheart.org/article/1306271.do [Accessed 10 January 2012]